Nature Communications (Dec 2019)
Structural basis of ligand selectivity and disease mutations in cysteinyl leukotriene receptors
- Anastasiia Gusach,
- Aleksandra Luginina,
- Egor Marin,
- Rebecca L. Brouillette,
- Élie Besserer-Offroy,
- Jean-Michel Longpré,
- Andrii Ishchenko,
- Petr Popov,
- Nilkanth Patel,
- Taku Fujimoto,
- Toru Maruyama,
- Benjamin Stauch,
- Margarita Ergasheva,
- Daria Romanovskaia,
- Anastasiia Stepko,
- Kirill Kovalev,
- Mikhail Shevtsov,
- Valentin Gordeliy,
- Gye Won Han,
- Vsevolod Katritch,
- Valentin Borshchevskiy,
- Philippe Sarret,
- Alexey Mishin,
- Vadim Cherezov
Affiliations
- Anastasiia Gusach
- Research Сenter for Molecular Mechanisms of Aging and Age-Related Diseases, Moscow Institute of Physics and Technology
- Aleksandra Luginina
- Research Сenter for Molecular Mechanisms of Aging and Age-Related Diseases, Moscow Institute of Physics and Technology
- Egor Marin
- Research Сenter for Molecular Mechanisms of Aging and Age-Related Diseases, Moscow Institute of Physics and Technology
- Rebecca L. Brouillette
- Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke
- Élie Besserer-Offroy
- Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke
- Jean-Michel Longpré
- Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke
- Andrii Ishchenko
- Bridge Institute, Michelson Center for Convergent Bioscience, University of Southern California
- Petr Popov
- Research Сenter for Molecular Mechanisms of Aging and Age-Related Diseases, Moscow Institute of Physics and Technology
- Nilkanth Patel
- Bridge Institute, Michelson Center for Convergent Bioscience, University of Southern California
- Taku Fujimoto
- Ono Pharmaceutical Co., Ltd.
- Toru Maruyama
- Ono Pharmaceutical Co., Ltd.
- Benjamin Stauch
- Bridge Institute, Michelson Center for Convergent Bioscience, University of Southern California
- Margarita Ergasheva
- Research Сenter for Molecular Mechanisms of Aging and Age-Related Diseases, Moscow Institute of Physics and Technology
- Daria Romanovskaia
- Research Сenter for Molecular Mechanisms of Aging and Age-Related Diseases, Moscow Institute of Physics and Technology
- Anastasiia Stepko
- Research Сenter for Molecular Mechanisms of Aging and Age-Related Diseases, Moscow Institute of Physics and Technology
- Kirill Kovalev
- Research Сenter for Molecular Mechanisms of Aging and Age-Related Diseases, Moscow Institute of Physics and Technology
- Mikhail Shevtsov
- Research Сenter for Molecular Mechanisms of Aging and Age-Related Diseases, Moscow Institute of Physics and Technology
- Valentin Gordeliy
- Research Сenter for Molecular Mechanisms of Aging and Age-Related Diseases, Moscow Institute of Physics and Technology
- Gye Won Han
- Bridge Institute, Michelson Center for Convergent Bioscience, University of Southern California
- Vsevolod Katritch
- Bridge Institute, Michelson Center for Convergent Bioscience, University of Southern California
- Valentin Borshchevskiy
- Research Сenter for Molecular Mechanisms of Aging and Age-Related Diseases, Moscow Institute of Physics and Technology
- Philippe Sarret
- Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke
- Alexey Mishin
- Research Сenter for Molecular Mechanisms of Aging and Age-Related Diseases, Moscow Institute of Physics and Technology
- Vadim Cherezov
- Research Сenter for Molecular Mechanisms of Aging and Age-Related Diseases, Moscow Institute of Physics and Technology
- DOI
- https://doi.org/10.1038/s41467-019-13348-2
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 9
Abstract
Cysteinyl leukotriene G protein-coupled receptors CysLT1 and CysLT2 regulate pro-inflammatory responses associated with allergic disorders. Here, authors describe four crystal structures of CysLT2R in complex with three dual CysLT1R/CysLT2R antagonists, which shed light on CysLTR ligand selectivity.
